Private Capital Management LLC Decreases Stock Holdings in Harrow, Inc. (NASDAQ:HROW)

Private Capital Management LLC cut its holdings in Harrow, Inc. (NASDAQ:HROW) by 21.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,694,983 shares of the company’s stock after selling 468,698 shares during the quarter. Harrow makes up 6.0% of Private Capital Management LLC’s holdings, making the stock its 2nd biggest holding. Private Capital Management LLC owned approximately 4.76% of Harrow worth $56,867,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Barclays PLC boosted its stake in Harrow by 301.9% in the third quarter. Barclays PLC now owns 52,593 shares of the company’s stock valued at $2,365,000 after buying an additional 39,506 shares in the last quarter. Brookstone Capital Management acquired a new stake in shares of Harrow during the fourth quarter valued at about $275,000. SG Americas Securities LLC boosted its stake in shares of Harrow by 158.5% during the fourth quarter. SG Americas Securities LLC now owns 30,689 shares of the company’s stock valued at $1,030,000 after purchasing an additional 18,815 shares in the last quarter. Sonora Investment Management Group LLC acquired a new stake in shares of Harrow during the fourth quarter valued at about $518,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of Harrow by 8.4% during the fourth quarter. Bank of New York Mellon Corp now owns 86,447 shares of the company’s stock valued at $2,900,000 after purchasing an additional 6,690 shares in the last quarter. 72.76% of the stock is owned by institutional investors and hedge funds.

Harrow Price Performance

Shares of HROW opened at $25.13 on Thursday. Harrow, Inc. has a 1 year low of $15.78 and a 1 year high of $59.23. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The company has a market capitalization of $921.89 million, a price-to-earnings ratio of -26.73 and a beta of 0.41. The business has a 50-day moving average of $24.85 and a 200-day moving average of $32.27.

Harrow (NASDAQ:HROW) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.40). Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The company had revenue of $47.83 million for the quarter, compared to the consensus estimate of $57.00 million. As a group, equities research analysts anticipate that Harrow, Inc. will post -0.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on HROW. HC Wainwright lifted their price target on Harrow from $57.00 to $60.00 and gave the company a “buy” rating in a research note on Monday. B. Riley cut their price target on Harrow from $69.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.